School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Shanghai Degron Therapeutics, Shanghai China.
Bioorg Med Chem. 2024 Apr 15;104:117683. doi: 10.1016/j.bmc.2024.117683. Epub 2024 Mar 18.
CRBN is a substrate receptor for the Cullin Ring E3 ubiquitin ligase 4 (CRL4) complex. It has been observed that CRBN can be exploited by small molecules to facilitate the recruitment and ubiquitination of non-natural CRL4 substrates, resulting in the degradation of neosubstrate through the ubiquitin-proteasome system. This phenomenon, known as molecular glue-induced protein degradation, has emerged as an innovative therapeutic approach in contrast to traditional small-molecule drugs. One key advantage of molecular glues, in comparison to conventional small-molecule drugs adhering to Lipinski's Rule of Five, is their ability to operate without the necessity for specific binding pockets on target proteins. This unique characteristic empowers molecular glues to interact with conventionally intractable protein targets, such as transcription factors and scaffold proteins. The ability to induce the degradation of these previously elusive targets by hijacking the ubiquitin-proteasome system presents a promising avenue for the treatment of recalcitrant diseases. Nevertheless, the rational design of molecular glues remains a formidable challenge due to the limited understanding of their mechanisms and actions. This review offers an overview of recent advances and breakthroughs in the field of CRBN-based molecular glues, while also exploring the prospects for a systematic approach to designing these compounds.
CRBN 是 Cullin 环 E3 泛素连接酶 4(CRL4)复合物的底物受体。已经观察到,小分子可以利用 CRBN 来促进非天然 CRL4 底物的招募和泛素化,导致通过泛素-蛋白酶体系统降解新底物。这种现象,称为分子胶诱导的蛋白质降解,与传统的小分子药物相比,是一种创新的治疗方法。与传统的符合 Lipinski 五规则的小分子药物相比,分子胶的一个关键优势是它们能够在不需要靶蛋白上特定结合口袋的情况下发挥作用。这种独特的特性使分子胶能够与通常难以处理的蛋白质靶标(如转录因子和支架蛋白)相互作用。通过劫持泛素-蛋白酶体系统来诱导这些以前难以捉摸的靶标的降解,为治疗难治性疾病提供了一个有前途的途径。然而,由于对其机制和作用的理解有限,分子胶的合理设计仍然是一个巨大的挑战。本综述概述了基于 CRBN 的分子胶的最新进展和突破,同时也探讨了系统设计这些化合物的前景。